These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15090834)

  • 1. Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population.
    Jensen-Fangel S; Pedersen L; Pedersen C; Larsen CS; Tauris P; Møller A; Sørensen HT; Obel N
    AIDS; 2004 Jan; 18(1):89-97. PubMed ID: 15090834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
    Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N
    Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: a nationwide population-based cohort study.
    Larsen MV; Omland LH; Gerstoft J; Røge BT; Larsen CS; Pedersen G; Obel N; Kronborg G
    Scand J Infect Dis; 2010 Dec; 42(11-12):917-23. PubMed ID: 20840000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.
    Wood E; Hogg RS; Yip B; Harrigan PR; O'Shaughnessy MV; Montaner JS
    Ann Intern Med; 2003 Nov; 139(10):810-6. PubMed ID: 14623618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hospitalization for pneumonia among individuals with and without HIV infection, 1995-2007: a Danish population-based, nationwide cohort study.
    Sogaard OS; Lohse N; Gerstoft J; Kronborg G; Ostergaard L; Pedersen C; Pedersen G; Sørensen HT; Obel N
    Clin Infect Dis; 2008 Nov; 47(10):1345-53. PubMed ID: 18834317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries.
    ; Zwahlen M; Harris R; May M; Hogg R; Costagliola D; de Wolf F; Gill J; Fätkenheuer G; Lewden C; Saag M; Staszewski S; d'Arminio Monforte A; Casabona J; Lampe F; Justice A; von Wyl V; Egger M
    Int J Epidemiol; 2009 Dec; 38(6):1624-33. PubMed ID: 19820106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy.
    Kohli R; Lo Y; Howard AA; Buono D; Floris-Moore M; Klein RS; Schoenbaum EE
    Clin Infect Dis; 2005 Sep; 41(6):864-72. PubMed ID: 16107987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
    J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study.
    Cozzi Lepri A; Phillips AN; d'Arminio Monforte A; Castelli F; Antinori A; de Luca A; Pezzotti P; Alberici F; Cargnel A; Grima P; Piscopo R; Prestileo T; Scalise G; Vigevani M; Moroni M;
    AIDS; 2001 May; 15(8):983-90. PubMed ID: 11399980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two decades of HIV infection in a cohort of haemophilic individuals: clinical outcomes and response to highly active antiretroviral therapy.
    Sabin CA; Yee TT; Devereux H; Griffioen A; Loveday C; Phillips AN; Lee CA
    AIDS; 2000 May; 14(8):1001-7. PubMed ID: 10853982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CMVR diagnoses and progression of CD4 cell counts and HIV viral load measurements in HIV patients on HAART.
    Zambarakji HJ; Newson RB; Mitchell SM
    Br J Ophthalmol; 2001 Jul; 85(7):837-41. PubMed ID: 11423459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients.
    Antiretroviral Therapy Cohort Collaboration
    J Acquir Immune Defic Syndr; 2007 Dec; 46(5):607-15. PubMed ID: 18043315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
    Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
    Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study.
    Rasmussen LD; Engsig FN; Christensen H; Gerstoft J; Kronborg G; Pedersen C; Obel N
    AIDS; 2011 Aug; 25(13):1637-46. PubMed ID: 21646903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.
    Hunt PW; Deeks SG; Rodriguez B; Valdez H; Shade SB; Abrams DI; Kitahata MM; Krone M; Neilands TB; Brand RJ; Lederman MM; Martin JN
    AIDS; 2003 Sep; 17(13):1907-15. PubMed ID: 12960823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata.
    Palella FJ; Deloria-Knoll M; Chmiel JS; Moorman AC; Wood KC; Greenberg AE; Holmberg SD;
    Ann Intern Med; 2003 Apr; 138(8):620-6. PubMed ID: 12693883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
    Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality and progression to AIDS after starting highly active antiretroviral therapy.
    van Sighem AI; van de Wiel MA; Ghani AC; Jambroes M; Reiss P; Gyssens IC; Brinkman K; Lange JM; de Wolf F;
    AIDS; 2003 Oct; 17(15):2227-36. PubMed ID: 14523280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.